The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro.
Cannabidiol is the main nonpsychoactive component of marijuana. We examined the ability of in vivo and in vitro cannabidiol to interfere with the production of interleukin (IL)-12 and IL-10 by murine macrophages and to modulate macrophage chemotaxis. Cannabidiol added in vitro to peritoneal macrophages significantly increased IL-12 and decreased IL-10 production. The CB1 and CB2 receptor antagonists prevented this modulation. Macrophages from animals treated with cannabidiol at the dose of 30 mg kg(-1) either orally or i.p. produced higher levels of IL-12 and lower levels of IL-10 in comparison to controls, and the CB receptor antagonists did not prevent these effects. Cannabidiol dose-dependently decreased fMLP-induced chemotaxis of macrophages, and the CB2 receptor antagonist prevented this decrease.
Sacerdote
P
P
Department of Pharmacology, via Vanvitelli 32, 20129 Milano, Italy. paola.sacerdote@unimi.it
Martucci
C
C
Vaccani
A
A
Bariselli
F
F
Panerai
A E
AE
Colombo
A
A
Parolaro
D
D
Massi
P
P
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology*; D000284:Administration, Oral; D000818:Animals; D001892:Camphanes / Q000494:pharmacology; D002185:Cannabidiol / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology*; D002464:Cell Migration Inhibition; D002478:Cells, Cultured; D002633:Chemotaxis / Q000187:drug effects* / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D015536:Down-Regulation / Q000187:drug effects / Q000276:immunology; D016753:Interleukin-10 / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D018664:Interleukin-12 / Q000096:biosynthesis*; D008262:Macrophage Activation / Q000187:drug effects / Q000276:immunology; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D008297:Male; D051379:Mice; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors / Q000502:physiology; D043885:Receptor, Cannabinoid, CB2 / Q000037:antagonists & inhibitors / Q000502:physiology; D000077285:Rimonabant; D015854:Up-Regulation / Q000187:drug effects / Q000276:immunology
D000276:Adjuvants, Immunologic; D001892:Camphanes; D016207:Cytokines; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; C110630:SR 144528; D016753:Interleukin-10; D018664:Interleukin-12; D002185:Cannabidiol; D000077285:Rimonabant